Monday, May 20, 2002

James Metz, MD, OncoLink Editor-in-Chief, and Stephen Hahn, MD, Associate Professor of Radiation Oncology at the Unversity of Pennsylvania

Dr. Heather Jones from the Department of Radiation at the Abramson Cancer Center of the University of Pennsylvania presents her poster. ...
...
A Phase II Trial Of Pemetrexed In Malignant Pleural Mesothelioma (MPM) Patients: Clinical Outcome, Role Of Vitamin Station, Respiratory Symptoms Upplemenand Lung Function Presenter: Dong M Shin,Presenter's Affiliation: University of PittsburghType of Session: ScientificBackground Malignant pleural mesothelia (MPM) is generally caused by exposure to asbestos and is commonly accompanied by pleural effusion, sometimes...
Cisplatin And Etoposide Plus Concurrent Accelerated Hyperfractionated Thoracic Radiotherapy (TRT) Followed By Three Cycles Of Irinotecan And Cisplatin For The Treatment Of Limited-Stage Small-Cell Lung Cancer (SCLC); Updated Results: JCOG 9903-DI Presenter: Kiyoshi MoriPresenter's Affiliation: National Cancer Center Hospital, Tokyo, Japan.Type of Session: ScientificBackground Noda K. et al have demonstrated that Irinotecan and cisplatin (IP) significantly improves survival compared with...
Initial Results Of Preoperative Gemcitabine (GEM)-Based Chemoradiation For Resectable Pancreatic Adenocarcinoma Presenter: Robert A WolffPresenter's Affiliation: UT MD Anderson Cancer Ctr, Houston, TXType of Session: ScientificBackground The recurrence rate in patients with adenocarcinoma of the pancreas following pancreaticoduodenectomy with curative intent...
Phase II Study Of STI571 (Gleevec^TM) For Patients With Small Cell Lung Cancer Presenter: Bruce E JohnsonPresenter's Affiliation: Dana-Farber Cancer Inst, Boston, MAType of Session: ScientificBackground STI571 is a small molecule that inhibits the tyrosine kinase activity of the BCR-Abl and Kit receptors The oral preparation...
Phase III single-blinded study of premexetred + cisplatin vs. cisplatin alone in chemonaive patients with malignant pleural mesothelioma Presenter: N.J. VogelzangPresenter's Affiliation: U of ChicagoType of Session: PlenaryBackground Mesothelioma is an aggressive malignancy with no consistent, proven benefit to any traditional treatment: surgery, radiation therapy, or any combination...
PSA Testing Interval Reduction In Screening Intervals: Data From The Prostate, Lung, Colorectal And Ovarian Cancer (PLCO) Screening Trial Presenter: E. D CrawfordPresenter's Affiliation: Univ of Colorado Health Sciences Ctr, Denver, COType of Session: PlenaryBackground Prostate cancer is the most commonly diagnosed malignancy in males and the second leading cause of cancer mortality in...
Randomized phase III trial in locally advanced esophageal cancer: radiochemotherapy followed by surgery versus radiochemotherapy alone (FFCD 9102) Presenter: L. BedennePresenter's Affiliation: Sevice de Hepato-Gastroenterologie-Chu-Le Bocage, Dijon-Cedex, FranceType of Session: ScientificBackground While surgical resection remains part of the standard of care for locally advanced esophageal...
Responding to the IOM?s Challenge to Improve Palliative Care: Nurse/Physician Collaborative Care Model In June of 2000, the Institute of Medicine issued a report addressing barriers to palliative care in the United States. From this report came a mandate for improvements in palliative care. A presentation at the ASCO annual meeting addressed the...
Risk-reducing salpingo-oopherectomy in women with BRCA1 and BRCA2 mutations Presenter: K. OffitPresenter's Affiliation: Memorial Sloan Kettering Cancer CenterType of Session: PlenaryBackground BRCA1 and BRCA2 mutations have been proven to place patients at higher risk for both breast cancer and ovarian cancer. Screening of...
Single-Agent (SA) Versus Combination Chemotherapy (CC) In Advanced Non-Small Cell Lung Cancer (NSCLC): A CALGB Randomized Trial Of Efficacy, Quality Of Life (QoL), And Cost-Effectiveness Presenter: Rogerio C LilenbaumPresenter's Affiliation: CALGBType of Session: PlenaryBackground The standard of care for patients with locally advanced NSCLC and good performance status (PS) is combination chemotherapy (CC). However, while CC has...
STI-571 (Gleevac/Glivec, imatinib) versus interferon (IFN) + cytarabine as initial therapy for patients with CML: results of a randomized study Presenter: B.J. DrukerPresenter's Affiliation: IRIS Study Group, Portland, ORType of Session: PlenaryBackground The standard therapy for newly diagnosed chronic myelogenous leukemia (CML) is interferon (IFN). The addition of cytarabine to IFN has...
SWOG 0004 - Pilot Study Of Tirapazamine (TPZ) Plus Cisplatin/Etoposide (PE) And Concurrent Thoracic Radiotherapy (RT) In Limited Small Cell Lung Cancer (LSCLC) Presenter: Quynh-Thu LePresenter's Affiliation: SWOGType of Session: ScientificBackground Tirapazamine (TPZ)is a novel hypoxic cytotoxin that has been proven to increase cell killing in hypoxic cells. TPZ has also demonstrated synergistic increases...